Alkermes plc (FRA:8AK)

Market Cap	5.91B +27.2%
Revenue (ttm)	1.35B +3.2%
Net Income	132.45M -56.7%
EPS	0.79 -56.5%
Shares Out	n/a
PE Ratio	44.65
Forward PE	24.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	35.11
Previous Close	35.78
Day's Range	35.11 - 35.96
52-Week Range	22.00 - 35.96
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About Alkermes

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 2,050
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AK

Financial Performance

In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.

Financial numbers in USD